文献速递眼底病与葡萄膜炎

IVAN试验结束后nAMD患者长期视觉结局随访

Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial.
PubMed 文献 · Ophthalmology · 2020-03-27

该多中心队列研究纳入IVAN试验退出后537例新生血管性年龄相关性黄斑变性患者,随访至数据收集时,中位监测3.3年,研究眼视力每年下降4.3个字母,注射频率和药物转换不影响视力变化。

要点

  • 研究眼中位监测3.3年,视力每年下降4.3个字母。
  • 调整协变量后,注射频率不影响视力变化率。
  • 32%患者退出后未治疗,93%首选雷珠单抗,23%转换为阿柏西普。

核心结论

  • IVAN试验结束约5年后,研究眼功能下降轨迹大于既往不完全试验队列报告。
  • 抗VEGF注射率和治疗转换不是决定视力结局的重要因素。

研究设计与样本

  • 多中心队列研究,随访至试验退出后7年。
  • 纳入IVAN试验537例患者,排除2个中心及死亡或退出者。
  • 数据收集于2016年5月26日至2017年8月24日。

主要发现

  • 研究眼监测中位持续时间3.3年(IQR 1.3-4.7),中位视力58.0字母(IQR 34.0-73.0)。
  • 研究眼视力每年下降4.3字母(95%CI 3.7-4.9)。
  • 退出后174例(32%)未接受治疗;358例中332例(93%)首选雷珠单抗,其中78例(23%)转换为阿柏西普。
  • 转换与未转换者研究监测结束时视力相似。

临床怎么用

  • 长期随访中需关注nAMD患者视力持续下降,即使持续治疗。
  • 注射频率和药物转换可能不是改善视力结局的关键因素。

局限性

  • 排除了2个中心及试验期间死亡或退出者,可能影响代表性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe visual outcomes, frequency of treatment and monitoring visits, and anti-vascular endothelial growth factor drugs used in usual care in participants who exited a trial in which treatment for neovascular age-related macular degeneration (nAMD) was initiated with bevacizumab or ranibizumab. DESIGN: Multicenter cohort study up to 7 years after trial exit. PARTICIPANTS: Patients enrolled in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) trial; after excluding participants from 2 sites and who died or withdrew during the trial, 537 were included in this follow-up cohort. METHODS: Data were collected between May 26, 2016, and August 24, 2017. Distance visual acuity (DVA) (letters read) in both eyes and treatments for nAMD administered to either eye at all usual care visits were extracted from medical records of all participants until the point of data collection (duration of study eye monitoring). MAIN OUTCOME MEASURES: Rate of change of DVA during active surveillance of the study eye (study eye monitoring), estimated using a multivariable linear random effects model. Other outcome measures were visit and treatment frequency and switches in anti-vascular endothelial growth factor (VEGF) drug. RESULTS: Data were obtained for 99% (532/537) of eligible participants. The median duration of study eye monitoring after IVAN exit was 3.3 years (interquartile range [IQR], 1.3-4.7), and median DVA was 58.0 letters (IQR, 34.0-73.0). Study eye DVA deteriorated by 4.3 (95% confidence interval [CI], 3.7-4.9) letters per year. Injection rate did not influence the rate of change in DVA after adjusting for key covariates. After IVAN exit, 174 participants (32%) received no treatment; 332 of 358 (93%) were treated first with ranibizumab, 78 (23%) of whom switched to aflibercept. The DVA was similar among participants who switched or did not switch at the end of study monitoring. CONCLUSIONS: Approximately 5 years after the IVAN study finished, with unprecedented completeness of follow-up for such a trial, the trajectory of functional decline in the study eye was shown to be greater than that previously reported for incomplete trial cohorts. Anti-VEGF injection rates and treatment switches were not important factors in determining visual acuity outcomes.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Evans RN, Reeves BC, Phillips D, et al. Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial. Ophthalmology. 2020. PMID: 32359843. doi:10.1016/j.ophtha.2020.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。